Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis

BACKGROUND: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GV...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarmiento Maldonado, Mauricio, Ramírez Villanueva, Pablo, Bertín Cortes-Monroy, Pablo, Jara Arias, Veronica, Soto Donoso, Katherine, Uribe Gonzalez, Pablo, Ocqueteau Tachini, Mauricio, Perez-Simón, Jose Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712115/
https://www.ncbi.nlm.nih.gov/pubmed/29214116
http://dx.doi.org/10.1186/s40164-017-0092-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712115/
https://www.ncbi.nlm.nih.gov/pubmed/29214116
http://dx.doi.org/10.1186/s40164-017-0092-3

Ejemplares similares